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Summary
  Haematopoietic stem cell transplantation is a therapeutic method which is not 
only used for the treatment of haematooncological diseases but also as a therapy 
for solid tumours and non-malignant diseases. Haematopoietic stem cell trans-
plantation inﬂ uences the further course of the disease and therefore the quali-
ty of life for patients in the same way as other therapeutic methods. The authors 
describe the evaluation possibilities for the quality of life and effect of selected 
aspects on quality of life of patients undergoing haematopoietic stem cell trans-
plantation in the form of a review of the literature.
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BACKGROUND
Haematopoietic stem cell transplantation (HSCT) 
is a modern therapeutic method used for bio-
modulation antitumour therapy of haematolog-
ical malignancies (acute and chronic leukaemia, 
malignant Hodgkin’s and non-Hodgkin’s lympho-
ma, multiple myeloma, etc.) and of solid tumours 
(Grawitz’s tumour of the kidney, breast carcino-
ma, testicular tumours, neuroblastoma, small cell 
lung carcinoma) [1,2]. It is also used for the ther-
apy of non-tumour and hereditary diseases (demy-
elinization disease – sclerosis multiplex, systemic 
disease – systemic lupus erythematodes, systemic 
sclerodermia and hereditary disease – Fanconi’s 
anaemia) [1,3]. It is divided into bone marrow 
transplantation (BMT), transplantation of stem 
(progenitor) cells (PSCT) and umbilical cord 
blood transplantation (UCBT) [2]. From a do-
nor’s point of view there are three kinds of trans-
plantation: syngenic transplantation (the donor 
is a monozygotic twin), allogeneic transplanta-
tion (HLA from a compatible sibling or parent or 
HLA from a compatible donor) and autologous 
transplantation (the patient is the donor).
AIM
The aim of HSCT is to replace a patient’s path-
ological bone marrow which contains tumorous 
cells with haematopoietic cells from a healthy 
donor and to restore haematopoiesis which is 
damaged by intensive antitumour therapy [1–3]. 
HSCT inﬂ uences the further course of disease 
and therefore the quality of life for patients in the 
same way as other therapeutic methods [4].
Quality of life (QoL) is generally deﬁ ned as “a 
patient´s subjective evaluation of his life situation” 
[5]. This deﬁ nition is based on Maslow´s theory 
of needs (the need to sleep, to eat, to drink etc.) 
[6]. The QoL term contains information on an 
individual´s physical, psychological, social and 
spiritual condition [7,8]. QoL evaluation is car-
ried out by means of generic and speciﬁ c ques-
tionnaires [4,5]. Generic questionnaires generally 
evaluate a patient´s overall condition regardless of 
his disease. Speciﬁ c questionnaires are designed 
for the evaluation of a patient’s overall condition 
in a particular type of disease. Modules are often 
used with these speciﬁ c questionnaires. These 
modules are focused on speciﬁ c symptoms and 
complaints in a particular type of disease [4,5]. 
The areas investigated in QoL questionnaires 
usually include a patient´s physical, psychologi-
cal and social functions, including his ﬁ nancial 
situation, his integration into society, including 
pain, quality of sleep, spiritual aspects (interests, 
hobbies) and also symptoms which are speciﬁ c 
to a particular disease [4–6].
I. TRANSPLANTATION TYPE AND QUALITY OF LIFE
A similar trend was discovered by Hacker [9] in 
his longitudinal study which was carried out from 
1990 to 2000 when he monitored the effect of 
HSCT type, in particular BMT (the ﬁ rst group 
of patients) and PSCT (the second group of pa-
tients), on QoL. Patients were tested by means 
of a generic SF-36 and a speciﬁ c FACT-BMT. De 
Souza [10] arrived at the same conclusions in 
a group of 26 patients (13 patients after BMT 
and 13 patients after PSCT) in his longitudi-
nal study which was carried out from 1995 to 
1999. Patients were tested by means of a gener-
ic World Health Organization Quality of Life 
Questionnaire (WHO QOL-100) and by means 
of the Hospital Anxiety and Depression Scale 
(HAD). The effect of HSCT on QoL accord-
ing to graft type (autologous and allogeneic) 
was monitored by Van Agthoven [11]. He car-
ried out a transversal study in a group of 91 pa-
tients (62 patients after autologous PSCT and 29 
patients after autologous BMT). These patients 
were randomly divided into 3 groups. Each group 
was tested by a different generic questionnaire. 
These questionnaires were presented to patients 
in the 3rd month after HSCT. We can state from 
the results of the study that all 3 questionnaires 
showed no difference in QoL between groups 
of patients depending on the type of transplan-
tation (there was the same QoL in patients after 
autologous and allogeneic PSCT). The opposite 
trend, i.e. a difference in QoL depending on the 
type of HSCT, was found by Lee [12]. He evalu-
ated QoL in a group of 10 patients with chronic 
Graft Versus Host Disease (cGVHD) after alloge-
neic HSCT. Methodologically the cGVHD mod-
ule – a speciﬁ c symptom 30-Item Symptom Scale 
in combination with a generic SF-36 (the ﬁ rst 
group with 5 patients) and in combination with 
a speciﬁ c FACT-BMT (the second group with 5 
patients) – was used. Lee [12] states that the QoL 
in patients after allogeneic HSCT is worse than 
in patients after autologous HSCT. The reason 
is the 30–90% cGVHD occurrence in patients af-
ter allogeneic HSCT. This negatively affects the 
QoL, which was conﬁ rmed by means of a speciﬁ c 
module in combination with generic and speciﬁ c 
QoL questionnaires. From other important stud-
ies which show a worse QoL in patients after allo-
geneic HSCT, we can mention Heinonen’s study 
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[13,14]. He tested in his longitudinal study 109 
patients after allogeneic HSCT (the 1st and the 5th 
year after this transplantation). Methodologically 
patients were tested by means of a speciﬁ c FACT-
BMT – Version 3. Another result of this study is 
that Heinonen [13,14] points out a higher QoL 
in patients after allogeneic HSCT depending on 
the lapse of time from this transplantation (the 
longer the lapse of time the better the QoL). This 
also depends on the manifestation or non-mani-
festation of cGVHD.
II. AGE AND QUALITY OF LIFE
De Souza [10], Heinonen [13,14], Chiodi [15], 
Wang [16], Wong [17], Andrykowski [18] and 
Zittoun [19] discovered a similar trend in their 
studies. De Souza [10] points out in his longitudi-
nal study conducted in a group of 26 patients (13 
patients after BMT and 13 patients after PSCT) 
a lower QoL in both groups of these patients. 
He found no differences according to the type 
of HSCT. Patients were tested by means of a ge-
neric WHO QOL-100 and HAD. De Souza (10) 
further explained his statements by the fact that 
with increasing age a number of associated dis-
eases can occur. These diseases reduce the QoL. 
Chiodi [15] also agrees with this opinion in his 
transversal study conducted in a group of 244 
patients with haematological malignancies after 
allogeneic BMT. He divided these patients into 
3 groups (the ﬁ rst group was 1 year after alloge-
neic BMT, the second group was 3 years after al-
logeneic BMT, and the third group was 5 years 
after allogeneic BMT). Methodologically pa-
tients were tested by means of the Psychosocial 
Adjustment to Illness Scale (PAIS). Chiodi [15] 
also points out the fact that in addition to poly-
morbidity a negative effect of cGVHD on a low-
er QoL in patients with increasing age should be 
stressed. Wang [16], Wong [17] and Andrykowski 
[18] also agree with the effect of cGVHD on a 
lower QoL in patients with increasing age. A lon-
gitudinal study conducted by Hayes [20] in 2004 
revealed an interesting piece of information. He 
compared the vital lung capacity in a group of 12 
patients after PSCT 1 week before this transplan-
tation and in the 2nd week and the 12th week after 
this transplantation. Hayes [20] recorded a high-
er QoL in patients with a higher level of overall 
physical ﬁ tness. It follows from this conclusion 
that with increasing age the level of overall phys-
ical ﬁ tness and also QoL decrease. Zittoun [19] 
discovered another interesting piece of informa-
tion in his transversal study conducted in a group 
of 179 patients with haematological malignancies 
after HSCT. He points out that increasing overall 
fatigue and emotional complaints which decrease 
QoL correlate with increasing age. Patients were 
tested by means of a speciﬁ c EORTC QLQ-C30, 
HAD and a speciﬁ c Leukaemia/BMT module. So 
[21] also discovered an interesting piece of in-
formation in his transversal study conducted in 
a group of 157 patients with haematological ma-
lignancies after BMT. He proved a high degree 
of overall fatigue in patients over the age of 50 
with associated diseases. Patients were tested by 
means of the Fatigue Scale – Chinese Version. 
Another author who agrees with Zittoun’s [19] 
and So’s [21] opinions is Saleh [22]. He con-
ducted a transversal study in a group of 41 pa-
tients after BMT. This author points out that in 
patients with an increasing number of associat-
ed diseases there is a lower overall physical con-
dition and this means a lower QoL. Patients were 
tested by means of a speciﬁ c QOL-BMT-ST 30 
months after BMT.
III. SEX AND QUALITY OF LIFE
De Souza [10] points out in his longitudinal study 
conducted in a group of 26 patients (13 patients 
after BMT and 13 patients after PSCT) a higher 
QoL in men in both types of HSCT compared to 
women again in both types of these transplanta-
tions. Patients were tested by means of a gener-
ic WHO QOL-100 and HAD. Heinonen [13,14] 
also agrees with De Souza’s results [10] in his lon-
gitudinal study conducted in a group of 109 pa-
tients after allogeneic HSCT. Patients were test-
ed by means of a speciﬁ c FACT-BMT – Version 3. 
The reason for a lower QoL in women compared 
to men is according to Heinonen [13,14] their 
emotional lability which is associated with the de-
manding process of HSCT. Chiodi [15] also has 
the same opinion in his transversal study conduct-
ed in a group of 244 patients with haematoonco-
logical diseases after allogeneic HSCT. In order 
to evaluate the effect of sex on QoL in patients 
after HSCT, Chiodi [15] used PAIS. Another au-
thor with the same opinion as Heinonen [13,14] 
and Chiodi [15] is Wang [16] with his transver-
sal study conducted in a group 95 patients after 
HSCT. Patients were tested by means of a spe-
ciﬁ c Functional Assessment Cancer Treatment 
– General Version Questionnaire (FACT-G). 
Signiﬁ cant differences in QoL between sexes of 
patients were not proven by Andrykowski [18] in 
his multicentre, longitudinal study conducted in 
a group of 200 patients with haematological ma-
lignancies after HSCT (46% of patients after allo-
geneic transplantation and 54% of patients after 
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autologous transplantation). Patients were tested 
by means of a speciﬁ c BMT-QoL. They were pre-
sented this questionnaire before this transplanta-
tion and the 1st year after this transplantation.
IV. LEVEL OF EDUCATION AND QUALITY OF LIFE
Henoinen [13,14] points out in his longitudinal 
study conducted in a group of 109 patients after 
allogeneic BMT a higher QoL in patients with 
higher education, meaning patients with second-
ary and university education. Patients were test-
ed by means of a speciﬁ c FACT-BMT – Version 3. 
This questionnaire was presented to patients in 
the 1st and the 5th year after this allogeneic BMT. 
Andrykowski [18] arrived at a similar conclusion 
in his multicentre longitudinal study conducted 
in a group of 200 patients with haematooncologi-
cal diseases after HSCT (46% of patients after al-
logeneic HSCT and 54% of patients after autolo-
gous HSCT). He proved a lower QoL in patients 
with lower education, meaning patients with el-
ementary and apprentice education. Patients 
were tested by means of a speciﬁ c BMT – QoL. 
They were presented this questionnaire before 
this transplantation and in the 1st year after this 
transplantation.
V. INCREASING NUMBER OF ASSOCIATED DISEASES AND 
QUALITY OF LIFE
Zittoun [19] discovered an interesting piece of in-
formation which showed a correlation among in-
creasing number of associated diseases, overall fa-
tigue and emotional difﬁ culties. Molassiotis [23] 
also agrees in his longitudinal study conducted in 
a group of 40 patients after BMT with the opinion 
which concerns emotional lability. He evaluated 
the emotional lability of these patients by means of 
the Emotional Difﬁ culties Scale (EDS). This scale 
was presented to patients before the BMT. Another 
scientist who agreed with this opinion was So [21] 
in his transversal study conducted in a group of 
157 patients with haematological malignancies af-
ter BMT. He proved a high degree of overall fa-
tigue in patients over the age of 50 with associat-
ed diseases. Patients were tested by means of the 
Fatigue Scale – Chinese Version. Saleh [22] and 
Slovacek [4] also agree in their transversal study 
conducted in patients after HSCT with Zittoun’s 
[19] and So’s [21] opinions. These authors stress 
the fact that in patients with an increasing number 
of associated diseases there is lower overall physi-
cal ﬁ tness and this causes a lower QoL. Heinonen 
[13,14] recorded in his longitudinal study con-
ducted in a group of 109 patients after alloge-
neic BMT a lower QoL in patients in connection 
with increasing number of associated diseases, in-
creased morbidity, increasing overall fatigue and 
worse quality of sleep. When he compared poly-
morbid men and women after allogeneic BMT he 
discovered a lower QoL in women. Edman [24] 
arrived at similar results in his transversal study 
conducted in a group of 25 Swedish patients af-
ter allogeneic PSCT. He states that increasing 
number of associated diseases is associated with 
greater physical complaints, increased morbidity, 
emotional lability (anxiety and depression), sex-
ual problems and sleep disorders. Patients were 
divided into 3 groups and then tested. The ﬁ rst 
group was tested by means of a generic Sickness 
Impact Proﬁ le (SIP). The second group was tested 
by means of the Frequency Intensity and Distress 
Scale (SFID-BMT) and the third group by means 
of the Sense of Coherence Scale (SOC). All three 
questionnaires evaluate subjective functional con-
dition, physical complaints and the ability to cope 
with a particular disease. Patients were tested 2 
years after allogeneic PSCT. Edman [24] found 
no differences in the QoL evaluation in patients 
after HSCT. However, physical complaints, sex-
ual problems, increased morbidity, anxiety, de-
pression and sleep disorders were recorded in all 
three questionnaires and in more than half of pa-
tients. In the same way as Heinonen [13,14] he 
points out that the above-mentioned complaints 
are connected with increasing number of associ-
ated diseases.
VI. MARITAL STATUS AND QUALITY OF LIFE
The effect of marital status on the QoL in patients 
after HSCT was proven by Saleh [22] in his trans-
versal study conducted in a group of 41 patients. 
Patients were tested by means of a speciﬁ c QOL-
BMT-ST. Saleh [22] states that marital status sig-
niﬁ cantly inﬂ uences QoL in patients after HSCT. 
Patients who are married have a higher QoL than 
single or divorced patients or patients who are wid-
owed. According to Saleh [22] functioning fam-
ily relationships and good friends inﬂ uence very 
positively the QoL in patients after HSCT. HSCT 
is very demanding from a patient’s point of view, 
especially as far as time is concerned. A patient is 
during the transplantation in the role of a social-
ly isolated person and a functioning family and 
good friends can help to eliminate this isolation. 
A similar trend was found by Heinonen [13,14] 
in his longitudinal study conducted in a group of 
109 patients after allogeneic BMT. He points out a 
higher QoL in patients who are married because 
of their good family and social relationships, and 
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in contrast a lower QoL in patients who are di-
vorced and lack these relationships. Heinonen 
[13,14] also monitored the QoL of life in divorced 
men and women. He arrived at a conclusion that 
divorced men have a lower QoL than divorced 
women. According to this author this is proba-
bly because of the continuing social isolation of 
divorced men after HSCT. Methodologically pa-
tients were tested by means of a speciﬁ c FACT-
BMT – Version 3. Another author who conﬁ rms 
the above-mentioned trend, i.e. a better QoL for 
patients with good family relationships, is Boyle 
[25]. He conducted a transversal study in a group 
of patients after autologous HSCT. According to 
Boyle [25] a well-functioning family and good so-
cial relationships positively inﬂ uence the QoL for 
patients. Baker [26] discovered in his longitudi-
nal study conducted in a group of 84 patients af-
ter BMT an interesting piece of information con-
cerning this issue. He proved that it is difﬁ cult for 
patients after BMT to integrate into their families 
or among their friends as a result of psychologi-
cal difﬁ culties – anxiety, depression and stigmati-
sation caused by the disease. Patients were tested 
by means of a generic Quality of Life Interview 
Questionnaire (QoLI) which evaluates 3 areas of 
psychosocial morbidity: 1. physical complaints – 
overall physical condition, overall fatigue and eat-
ing difﬁ culties, 2. psychological difﬁ culties – self-
control, anxiety, depression and worries about the 
future, 3. problems of social reintegration – fami-
ly, friends, social role, ﬁ nancial situation and stig-
matisation. Patients were tested in the 6th and the 
12th month after BMT.
VII. RELIGION AND QUALITY OF LIFE
Slovacek [4] recorded that QoL in patients after 
HSCT who believed in God was higher than in 
patients who were non-believers. Patients were 
tested by means of generic Euro QoL. The study 
was transversal and retrospective; the number of 
patients was 71. Entonen [27] and Bach [28] re-
corded these changes in values in patients after 
BMT. The above-mentioned changes often mean 
that the patient has to stop various activities, in-
cluding his interests and hobbies. Boyd [6] found 
signiﬁ cant changes in patients after HSCT who 
believed in God. Patients who believed in God 
had a higher QoL than non-believers.
VIII. TIME LAPSE FROM TRANSPLANTATION AND QUALITY 
OF LIFE
Broers [30] points out in his longitudinal study 
conducted in a group of 125 patients a higher 
QoL in patients in the 3rd year after HSCT com-
pared to patients in the 1st and 6th month and the 
1st year after this transplantation whose QoL was 
lower or at the same level. Patients were tested by 
means of a generic General Health Questionnaire 
(GHQ). Sutherland [31] has a similar opinion 
in his transversal study conducted in a group of 
251 patients after allogeneic BMT. He proved 
no signiﬁ cant differences in QoL in patients 40 
months after allogeneic BMT. Patients were test-
ed by means of MOS SF-36 and SLDS – BMT. 
Kopp [32,33] discovered the opposite trend 
[20,21] in his transversal study conducted in a 
group of 56 patients after BMT. These patients 
were divided into two groups. The ﬁ rst group 
with 15 patients was tested by means of a specif-
ic EORTC QLQ-C30 in the 1st year after BMT, 
the second group with 41 patients was tested by 
means of a speciﬁ c FACT-BMT more than a year 
after BMT. He proved no signiﬁ cant differences 
in the QoL evaluation carried out by means of 
the above-mentioned speciﬁ c questionnaires but 
he proved a higher QoL in patients more than a 
year after this BMT. According to Kopp [32,33] 
a worse QoL in patients in the 1st year after BMT 
is mainly inﬂ uenced by “insufﬁ cient” adaptation 
to the given disease and as well to “BMT” itself. 
Saleh [22] and Duraes [34] arrived at a similar 
conclusion. Saleh [22] found in his longitudi-
nal study conducted in a group of 41 patients 
after BMT signiﬁ cant differences in QoL before 
transplantation and 30 months after this trans-
plantation: a lower QoL before BMT compared 
to QoL after the transplantation. Patients were 
tested by means of a speciﬁ c Qol-BMT-ST. Duraes 
[34] proved in his longitudinal study conducted 
in a group of 60 patients after allogeneic HSCT 
signiﬁ cant changes in the time lapse from this 
transplantation: the longer the time lapse from 
this allogeneic HSCT, the higher was the QoL 
recorded. Patients were tested by means of a ge-
neric WHO QOL-100 and HAD before and af-
ter this transplantation.
CONCLUSIONS
It is common in clinical practice to evaluate a 
patient´s health condition and the success of the 
treatment based only on one type of marker, the 
most often by means of somatic, laboratory or de-
tecting markers [4]. However, the trend in mod-
ern medicine is to evaluate a patient´s health con-
dition in a more complex way, using other aspects. 
QoL means a higher dimensional evaluation of a 
number of life aspects. Different aspects can be 
affected in different ways in different phases of 
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the disease and its treatment. That is why this in-
formation enriches our knowledge concerning 
patients’ needs, and it can signiﬁ cantly contrib-
ute to the improvement of medical treatment. It 
can also help us to reveal the mechanisms which 
modify the origin and the course of disease [4]. 
There is very good experience abroad with the 
“Quality of Life Team”, which consists of a treat-
ing physician (in the case of HSCT it is a hae-
matologist), a transplantologist, nurses who are 
educated in the problem of QoL for patients, 
a clinical psychologist, a psychotherapist, a so-
cial worker and also a data manager [4]. The 
reason to establish these special teams is that by 
providing care to the patient and support to his 
family a good environment for the patient af-
ter HSCT can be created after his return home. 
This good environment can help the patient to 
adapt well [23].
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